Vanguard Global Advisers
OBIO icon

Vanguard Global Advisers’s Orchestra BioMed OBIO Stock Holding History

Vanguard Global Advisers’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.2K Hold
13,948
– – ﹤0.01% 3003
2026
Q1 		$59.3K Buy
+13,948
New +$59.4K ﹤0.01% 2944

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Vanguard Global Advisers's OBIO Position: Q2 2026 in Review

Vanguard Global Advisers held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 13,948 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

Vanguard Global Advisers first reported a position in OBIO in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Vanguard Global Advisers held 13,948 shares of Orchestra BioMed worth $60.2K as of Q2 2026.
  • Vanguard Global Advisers left its Orchestra BioMed share count unchanged in Q2 2026.
  • Orchestra BioMed made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3003 holding.
  • Vanguard Global Advisers first reported a position in Orchestra BioMed in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.